Frazier Management LLC
- SEC CIK
- 0001032165
- Latest filing
- Nov 14, 2022
Holdings in Q1 2021
Holdings as of Mar 31, 2021, filed May 12, 2021. Long positions only.
- Positions
- 35
- No 13F data for Q4 2020
- Portfolio value
- $1.25B
- No 13F data for Q4 2020
Livermore's 13F data starts with Q1 2021, so this quarter has no previous quarter to compare with and changes are not shown.
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| ARQTArcutis Biotherapeutics, Inc. | COM | 10,542,790 | $305.0M | 24.5% | – | – | History |
| PHATPhathom Pharmaceuticals, Inc. | COM | 5,827,415 | $218.9M | 17.6% | – | – | History |
| PASGPassage BIO, Inc. | COM | 5,009,219 | $87.6M | 7.0% | – | – | History |
| MIRMMirum Pharmaceuticals, Inc. | COM | 3,566,912 | $70.7M | 5.7% | – | – | History |
| KRYSKrystal Biotech, Inc. | COM | 895,000 | $69.0M | 5.5% | – | – | History |
| TARSTarsus Pharmaceuticals, Inc. | COM | 1,917,157 | $61.8M | 5.0% | – | – | History |
| PCVXVaxcyte, Inc. | COM | 2,309,554 | $45.6M | 3.7% | – | – | History |
| IOVAIovance Biotherapeutics, Inc. | COM | 1,312,999 | $41.6M | 3.3% | – | – | History |
| Translate Bio, Inc.89374L104 | COM | 2,182,789 | $36.0M | 2.9% | – | – | – |
| Trillium Therapeutics Inc.89620X506 | COM NEW | 3,123,107 | $33.4M | 2.7% | – | – | – |
| SNDXSyndax Pharmaceuticals Inc | COM | 1,435,045 | $32.1M | 2.6% | – | – | History |
| ALPNAlpine Immune Sciences, Inc. | COM | 2,571,450 | $27.3M | 2.2% | – | – | History |
| STROSutro Biopharma, Inc. | COM | 1,001,421 | $22.8M | 1.8% | – | – | History |
| ANABAnaptysbio, Inc | COM | 899,700 | $19.4M | 1.6% | – | – | History |
| ACRSAclaris Therapeutics, Inc. | COM | 696,000 | $17.5M | 1.4% | – | – | History |
| MTEMMolecular Templates, Inc. | COM | 1,374,047 | $17.3M | 1.4% | – | – | History |
| ISEEIVERIC bio, Inc. | COM | 2,544,500 | $15.7M | 1.3% | – | – | History |
| Frazier Lifesciences Acqu CoG3710A121 | UNIT 12/09/2025 | 1,501,000 | $15.3M | 1.2% | – | – | – |
| ADVMAdverum Biotechnologies, Inc. | COM | 1,437,028 | $14.2M | 1.1% | – | – | History |
| RGNXREGENXBIO Inc. | COM | 351,954 | $12.0M | 1.0% | – | – | History |
| GRTSGritstone bio, Inc. | COM | 1,030,878 | $9.72M | 0.8% | – | – | History |
| APTXAptinyx Inc. | COM | 3,190,079 | $9.57M | 0.8% | – | – | History |
| EPIXESSA Pharma Inc. | COM NEW | 316,616 | $9.20M | 0.7% | – | – | History |
| IMVTImmunovant, Inc. | COM | 508,000 | $8.15M | 0.7% | – | – | History |
| SRRKScholar Rock Holding Corp | COM | 156,000 | $7.90M | 0.6% | – | – | History |
| Freeline Therapeutics Hldgs35655L107 | SPONSORED ADS | 550,000 | $6.76M | 0.5% | – | – | – |
| EPZMEpizyme, Inc. | COM | 739,369 | $6.44M | 0.5% | – | – | History |
| AVDLAvadel Pharmaceuticals PLC | SPONSORED ADR | 578,104 | $5.23M | 0.4% | – | – | History |
| Bellus Health Inc New07987C204 | COM NEW | 1,296,743 | $4.95M | 0.4% | – | – | – |
| ALNAAllena Pharmaceuticals, Inc. | COM | 3,330,373 | $4.63M | 0.4% | – | – | History |
| SRRASierra Oncology, Inc. | COM NEW | 202,803 | $3.49M | 0.3% | – | – | History |
| CRDFCardiff Oncology, Inc. | COM | 293,500 | $2.72M | 0.2% | – | – | History |
| ITRMIterum Therapeutics plc | SHS | 1,538,316 | $2.17M | 0.2% | – | – | History |
| GRTXGalera Therapeutics, Inc. | COM | 241,000 | $2.13M | 0.2% | – | – | History |
| Nabriva Therapeutics plcG63637113 | SHS | 425,650 | $707.0K | 0.1% | – | – | – |